.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,544,713

« Back to Dashboard

Claims for Patent: 7,544,713

Title:Compounds and methods for delivery of prostacyclin analogs
Abstract: This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula: ##STR00001##
Inventor(s): Phares; Ken (Chapel Hill, NC), Mottola; David (Cary, NC)
Assignee: United Therapeutics Corporation (Silver Spring, MD)
Application Number:11/603,116
Patent Claims: 1. A method of treating pulmonary hypertension comprising orally administering a pharmaceutically effective amount of a compound of structure II to a subject in need thereof: ##STR00032## wherein, R.sup.1 is independently selected from the group consisting of H, substituted and unsubstituted alkyl groups, arylalkyl groups and groups wherein OR.sup.1 form a substituted or unsubstituted glycolamide ester; R.sup.2 and R.sup.3 may be the same or different and are independently selected from the group consisting of H, phosphate and groups wherein OR.sup.2 and OR.sup.3 form esters of amino acids or proteins, with the proviso that all of R.sup.1, R.sup.2 and R.sup.3 are not H; enantiomers thereof; and a pharmaceutically acceptable salt of the compound.

2. The method of claim 1, wherein when OR.sup.1 forms a substituted or unsubstituted glycolamide ester, R.sup.1 is --CH.sub.2CONR.sup.4R.sup.5, wherein R.sup.4 and R.sup.5 may be the same or different and are independently selected from the group consisting of H, OH, substituted and unsubstituted alkyl groups,--(CH.sub.2).sub.mCH.sub.3, --CH.sub.2OH, and --CH.sub.2(CH.sub.2).sub.n OH, with the proviso that m is 0, 1, 2, 3 or 4, and n is 0,1,2,3 or 4.

3. The method of claim 2, wherein R.sup.1 is a C.sub.1-C.sub.4 alkyl group.

4. The method of claim 3, wherein R1 is selected from the group consisting of methyl, ethyl, propyl or butyl.

5. The method of claim 1, wherein R.sup.1 is a substituted or unsubstituted benzyl group.

6. The method of claim 5, wherein R.sup.1 is --CH.sub.3 or --CH.sub.2C.sub.6H.sub.5.

7. The method of claim 2, wherein R.sup.4 and R.sup.5 are the same or different and are independently selected from the group consisting of H, OH, --CH.sub.3, and --CH.sub.2CH.sub.2OH.

8. The method of claim 1, wherein one or both of R.sup.2 and R.sup.3 are H.

9. The method of claim 1, wherein one or both of R.sup.2 and R.sup.3 are not H and R.sup.2 and R.sup.3 are independently selected from phosphate and groups wherein OR.sup.2 and OR.sup.3 are esters of amino acids, dipeptides, esters of tripeptides and esters of tetrapeptides.

10. The method of claim 1, wherein only one of R.sup.2 or R.sup.3 is a phosphate group.

11. The method of claim 9, wherein R.sup.2 and R.sup.3 are independently selected from groups wherein OR.sup.2 and OR.sup.3 are esters of amino acids.

12. The method of claim 11, wherein one or both of R.sup.2 and R.sup.3 are esters of glycine or alanine.

13. The method of claim 9, wherein one of R.sup.1 is H.

14. The method of claim 9, wherein one of R.sup.1 and R.sup.2 is H.

15. The method of claim 14, wherein R.sup.2 is H.

16. The method of claim 1, wherein the oral bioavailability of the compound is greater than the oral bioavailability of treprostinil.

17. The method of claim 16, wherein the oral bioavailability of the compound is at least 50% greater than the oral bioavailability of treprostinil.

18. The method of claim 17, wherein the oral bioavailability of the compound is at least 100% greater than the oral bioavailability of treprostinil.

19. The method of claim 1, further comprising administering pharmaceutically effective amount of a p-glycoprotein inhibitor.

20. The method of claim 19, wherein the p-glycoprotein inhibitor is administered simultaneously with the compound of structure II.

21. The method of claim 19, wherein the p-glycoprotein inhibitor is administered prior to administration of the compound of structure II.

22. The method of claim 19, wherein the p-glycoprotein inhibitor is administered orally or intravenously.

23. A method of treating pulmonary hypertension comprising orally administering to a subject in need thereof an effective amount of a compound of the following structure: ##STR00033##

24. The method of claim 23, wherein the compound melts at about 107.degree. C.

25. The method of claim 24, wherein the compound has an x-ray powder diffraction pattern having a pattern peak at about 17.2 degrees 2 theta.

26. A method of treating peripheral vascular disease, promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation, providing cytoprotection, preventing atherogenesis, or inducing angiogenesis comprising orally administering a pharmaceutically effective amount of a compound of structure II to a subject in need thereof: ##STR00034## wherein, R.sup.1 is independently selected from the group consisting of H, substituted and unsubstituted alkyl groups, arylalkyl groups and groups wherein OR.sup.1 form a substituted or unsubstituted glycolamide ester; R.sup.2 and R.sup.3 may be the same or different and are independently selected from the group consisting of H, phosphate and groups wherein OR.sup.2 and OR.sup.3 form esters of amino acids or proteins, with the proviso that all of R.sup.1, R.sup.2 and R.sup.3 are not H; enantiomers thereof; and a pharmaceutically acceptable salt of the compound.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc